Your browser is no longer supported. Please, upgrade your browser.
STSA Satsuma Pharmaceuticals, Inc. weekly Stock Chart
STSA [NASD]
Satsuma Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.42 Insider Own0.10% Shs Outstand17.40M Perf Week-11.88%
Market Cap73.32M Forward P/E- EPS next Y-1.51 Insider Trans-43.55% Shs Float12.70M Perf Month-83.24%
Income-42.10M PEG- EPS next Q-0.70 Inst Own79.90% Short Float2.21% Perf Quarter-86.40%
Sales- P/S- EPS this Y-255.00% Inst Trans0.61% Short Ratio0.12 Perf Half Y-78.33%
Book/sh5.40 P/B0.76 EPS next Y39.60% ROA-35.80% Target Price- Perf Year-72.80%
Cash/sh5.21 P/C0.78 EPS next 5Y- ROE-39.00% 52W Range3.95 - 36.10 Perf YTD-79.27%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-88.70% Beta-
Dividend %- Quick Ratio15.10 Sales past 5Y- Gross Margin- 52W Low3.29% ATR1.31
Employees20 Current Ratio15.10 Sales Q/Q- Oper. Margin- RSI (14)14.36 Volatility6.20% 12.39%
OptionableNo Debt/Eq0.04 EPS Q/Q-65.70% Profit Margin- Rel Volume0.28 Prev Close4.10
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume2.26M Price4.08
Recom2.80 SMA20-68.16% SMA50-79.67% SMA200-81.39% Volume641,883 Change-0.49%
Sep-11-20Downgrade SVB Leerink Outperform → Mkt Perform
Sep-11-20Downgrade Mizuho Buy → Neutral $32 → $4
Sep-11-20Downgrade Credit Suisse Outperform → Neutral $33 → $4
Jul-27-20Initiated H.C. Wainwright Buy $35
Feb-06-20Initiated Mizuho Buy
Oct-08-19Initiated SVB Leerink Outperform
Oct-08-19Initiated Credit Suisse Outperform $16
Sep-11-20 10:12AM  
08:05AM  
Sep-10-20 11:39AM  
08:00AM  
Sep-03-20 06:57PM  
Aug-12-20 01:55AM  
Aug-06-20 04:01PM  
Jul-27-20 09:33AM  
Jul-07-20 04:01PM  
Jun-11-20 04:05PM  
Jun-10-20 02:26PM  
Jun-01-20 04:05PM  
May-27-20 08:30AM  
May-18-20 04:05PM  
May-12-20 04:01PM  
Apr-28-20 04:05PM  
Mar-10-20 04:01PM  
Mar-05-20 04:01PM  
Feb-18-20 08:00AM  
Jan-28-20 04:05PM  
Dec-16-19 01:47PM  
Nov-26-19 07:00AM  
Nov-12-19 04:01PM  
Sep-20-19 08:00PM  
03:28PM  
Sep-17-19 04:01PM  
Sep-13-19 04:12PM  
Sep-12-19 07:30PM  
Sep-11-19 03:31PM  
Sep-03-19 08:00AM  
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled, single-use, and nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
O'Neil Thomas P.Chief Financial OfficerSep 01Option Exercise4.567503,420750Sep 03 04:05 PM
ALBRECHT DETLEFChief Medical OfficerSep 01Option Exercise4.561,0004,56021,212Sep 03 04:06 PM
O'Neil Thomas P.Chief Financial OfficerSep 01Sale22.1975016,6450Sep 03 04:05 PM
ALBRECHT DETLEFChief Medical OfficerSep 01Sale22.211,00022,21020,212Sep 03 04:06 PM
O'Neil Thomas P.Chief Financial OfficerAug 05Option Exercise4.561,0004,5601,000Aug 07 06:40 PM
O'Neil Thomas P.Chief Financial OfficerAug 05Sale25.001,00025,0000Aug 07 06:40 PM
ALBRECHT DETLEFChief Medical OfficerAug 03Option Exercise4.561,0004,56021,012Aug 05 04:03 PM
ALBRECHT DETLEFChief Medical OfficerAug 03Sale22.911,00022,90620,212Aug 05 04:03 PM
ALBRECHT DETLEFChief Medical OfficerJul 01Option Exercise4.561,0004,56020,812Jul 02 04:13 PM
O'Neil Thomas P.Chief Financial OfficerJul 01Option Exercise4.561,0004,560394Jul 02 04:15 PM
ALBRECHT DETLEFChief Medical OfficerJul 01Sale26.681,00026,68320,212Jul 02 04:13 PM
O'Neil Thomas P.Chief Financial OfficerJul 01Sale26.651,00026,6540Jul 02 04:15 PM
O'Neil Thomas P.Chief Financial OfficerJun 23Option Exercise1.042,1152,2002,115Jun 24 04:53 PM
O'Neil Thomas P.Chief Financial OfficerJun 23Sale35.232,11574,5120Jun 24 04:53 PM
O'Neil Thomas P.Chief Financial OfficerJun 01Option Exercise4.561,0004,5601,000Jun 02 07:31 PM
ALBRECHT DETLEFChief Medical OfficerJun 01Option Exercise4.561,0004,56021,212Jun 02 07:33 PM
ALBRECHT DETLEFChief Medical OfficerJun 01Sale25.261,00025,25720,212Jun 02 07:33 PM
O'Neil Thomas P.Chief Financial OfficerJun 01Sale25.321,00025,3240Jun 02 07:31 PM
O'Neil Thomas P.Chief Financial OfficerMay 20Option Exercise4.562,0009,1202,000May 21 05:34 PM
O'Neil Thomas P.Chief Financial OfficerMay 20Sale25.002,00050,0000May 21 05:34 PM
ALBRECHT DETLEFChief Medical OfficerMay 05Option Exercise4.561,0004,56021,212May 06 07:47 PM
ALBRECHT DETLEFChief Medical OfficerMay 05Sale20.001,00020,00020,212May 06 07:47 PM
ALBRECHT DETLEFChief Medical OfficerApr 14Option Exercise4.568003,64820,812Apr 16 04:12 PM
ALBRECHT DETLEFChief Medical OfficerApr 14Sale20.0080016,00020,012Apr 16 04:12 PM
ALBRECHT DETLEFChief Medical OfficerApr 01Option Exercise4.5620091220,412Apr 03 04:11 PM
ALBRECHT DETLEFChief Medical OfficerApr 01Sale20.252004,04920,012Apr 03 04:11 PM
ALBRECHT DETLEFChief Medical OfficerMar 11Option Exercise4.561,0004,56021,212Mar 12 05:32 PM
O'Neil Thomas P.Chief Financial OfficerMar 11Option Exercise4.561,0004,5601,000Mar 12 05:31 PM
ALBRECHT DETLEFChief Medical OfficerMar 11Sale27.421,00027,42220,212Mar 12 05:32 PM
O'Neil Thomas P.Chief Financial OfficerMar 11Sale27.681,00027,6780Mar 12 05:31 PM